Company Profile

GLAND PHARMA LTD.

NSE : GLANDBSE : 543245ISIN CODE : INE068V01023Industry : Pharmaceuticals & DrugsHouse : Private
BSE3561.0030.7 (+0.87 % )
PREV CLOSE (Rs.) 3530.30
OPEN PRICE (Rs.) 3522.40
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 7765
TODAY'S LOW / HIGH (Rs.)3522.00 3613.90
52 WK LOW / HIGH (Rs.)2050 4350
NSE3578.75 57.85 (+1.64 % )
PREV CLOSE(Rs.) 3520.90
OPEN PRICE (Rs.) 3511.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 3578.75 (176 )
VOLUME 145618
TODAY'S LOW / HIGH(Rs.) 3511.00 3610.75
52 WK LOW / HIGH (Rs.)2071 4350

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.00
TTM EPS (Rs.) 68.01
P/E Ratio 52.52
Book Value (Rs.) 401.44
Face Value (Rs.) 1
MCap (Rs. in Mn) 586853.43
Price/Earning (TTM) 48.16
Price/Sales (TTM) 14.74
Price/Book (MRQ) 8.90
PAT Margin (%) 28.79
ROCE (%) 28.00
Incorporation Year : 1978

Management Info :

Yiu Kwan Stanley Lau - Chairman Srinivas Sadu - Managing Director

Registered Office :

Address : Survey No. 143-148, 150 & 151,Near Gandimaisamma 'x' Roads, D. P. Pally,Dundigal Gandimaisamma Mandal, Medchal-malkajgiri District,
Hyderabad,
Telangana-500043

Phone : 040 3051 0999

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
09Dec12-09-2021$Gland Pharma rises on receiving USFDA’s tentative approval for Cangrelor for Injection Gland Pharma rises on receiv

Gland Pharma is currently trading at Rs. 3585.55, up by 55.25 points or 1.57% from its previous closing of Rs. 3530.30 on the BSE.

The scrip opened at Rs. 3522.40 and has touched a high and low of Rs. 3613.90 and Rs. 3522.00 respectively. So far 1033 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 4350.00 on 12-Aug-2021 and a 52 week low of Rs. 2050.00 on 16-Dec-2020.

Last one week high and low of the scrip stood at Rs. 3698.00 and Rs. 3507.00 respectively. The current market cap of the company is Rs. 58003.49 crore.

The promoters holding in the company stood at 58.02%, while Institutions and Non-Institutions held 22.76% and 19.21% respectively.

Gland Pharma has received a tentative approval from the United States Food and Drug Administration (USFDA) for Cangrelor for Injection, 50 mg/vial Single-Dose Vials. The company is amongst one of the first to files for this product and may be eligible for 180 days of generic drug exclusivity. The company will launch the product with its marketing partner on receipt of final approval.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in over 60 countries, including the US, Canada, Australia and India.

Gland Pharma is currently trading at Rs. 3585.55, up by 55.25 p..
09Dec12-09-2021$HCL Technologies, Tata Motors and Gland Pharma to see action today HCL Technologies, Tata Motor

HCL Technologies (HCL) and Deutsche Apotheker- und Arztebank eG (apoBank), the largest cooperative primary bank in Germany, have signed with Atruvia AG an agreement to acquire IT consulting company Gesellschaft für Banksysteme GmbH (gbs). The transaction, worth 99,000 euros, is expected to close in January 2022, subject to closing conditions, including regulatory approvals. Post-closing, HCL will own 51 per cent, while apoBank will own 49 per cent stake of gbs. apoBank is currently a 10 per cent shareholder in gbs.

Tata Motors has reportedly lined up an investment of more than $1 billion (over Rs 7,500 crore) in the coming 4-5 years to recraft its road map for the commercial vehicle business, with electric vehicles at its core.

Gland Pharma has received a tentative approval from the United States Food and Drug Administration (USFDA) for Cangrelor for Injection, 50 mg/vial Single-Dose Vials. The company is amongst one of the first to files for this product and may be eligible for 180 days of generic drug exclusivity. The company will launch the product with its marketing partner on receipt of final approval.

Bharti Airtel has selected Juniper Networks to deliver network upgrades for the expansion of Airtel's nationwide broadband coverage across India. Airtel has expanded its Fibre-to-the-Home broadband coverage to over 430 towns with plans of covering 30 million households in over 2,000 cities in the next three years.

Mahindra Group and Reliance BP Mobility (RBML), operating under the brand name Jio-bp, have signed non-binding Memorandum of Understanding (MoU) for exploring creation of EV products and services, alongside identifying synergies in low-carbon and conventional fuels. The MoU also covers evaluating charging solutions by Jio-bp for Mahindra vehicles including electric 3 and 4 wheelers, quadricycles and e-SCV (Small Commercial Vehicles – sub 4 ton). This would include captive fleets and last-mile mobility vehicles of Mahindra Group.

Vishwaraj Sugar Industries has entered into contracts with oil marketing companies (OMC) for supplying of 2.50 crore liters of ethanol commencing from December 2021 as against the supply of 2.25 crore liters of ethanol during the twelve month period ended on November 30, 2021. The Company has already commenced supply of ethanol for the current period.

Action Construction Equipment has received order for supply of 38 nos. Mobile Crane to SPIC, Defence R&D Organization (Ministry of Defence) for a total consideration of approximately Rs 6.51 crore.

HCL Technologies (HCL) and Deutsche Apotheker- und Arztebank eG..
08Dec12-08-2021$Gland Pharma receives USFDA’s tentative approval for Cangrelor for Injection Gland Pharma receives USFDAâ

Gland Pharma has received a tentative approval from the United States Food and Drug Administration (USFDA) for Cangrelor for Injection, 50 mg/vial Single-Dose Vials. The company is amongst one of the first to files for this product and may be eligible for 180 days of generic drug exclusivity. The company will launch the product with its marketing partner on receipt of final approval.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in over 60 countries, including the US, Canada, Australia and India.

Gland Pharma has received a tentative approval from the United..
08Dec12-08-2021$Gland Pharma informs about analyst meet Gland Pharma informs about a

Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, Gland Pharma has informed that it enclosed the schedule of Analyst/ Institutional Investor Meetings with the Company to be held on December 08, 2021. The schedule of the mentioned meetings is subject to change and the change may occur due to exigencies on the part of Investor/ Analyst/ Company.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 read with Part A of the Securities an..
01Dec12-01-2021$Gland Pharma informs about analyst meet Gland Pharma informs about a
Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, Gland Pharma has informed that it enclosed the schedule of Analyst/ Institutional Investor Meetings with the Company.

The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 read with Part A of the Securities an..
Financials More
Rs. in Millions
QTR Sep 21 ANNUAL 21
Net Profit3021.29970.05
Gross Profit 4007.04 13348.52
Operating Profit 4278.3814370.43
Net Sales 10804.6934628.76
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
TTK Healthcare (BSE)
 770.00 (13.30%)
M.Cap ( in Cr)
1093.41
Ajanta Pharma (BSE)
 2132.05 (1.78%)
M.Cap ( in Cr)
17920.69
Natco Pharma (BSE)
 866.75 (3.88%)
M.Cap ( in Cr)
15768.58
Glaxosmithkline Phar (BSE)
 1876.00 (1.75%)
M.Cap ( in Cr)
31519.69
Dr. Reddy's Lab (BSE)
 4600.75 (0.65%)
M.Cap ( in Cr)
76111.33
Shareholding Pattern More
PROMOTERS 58.02 %
NON-INSTITUTION 19.21 %
MUTUAL FUNDS/UTI 10.98 %
FI/BANKS/INSURANCE 0.41 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes